Epitopes mapped onto SARS-CoV-2 receptor-binding motif by five distinct human neutralising antibodies

References

• Makela MJ, Puhakka T, Ruuskanen O, et al. Viruses and bacteria in the etiology of the common cold. J Clin Microbiol. 1998;36(2):539–542.
   PubMed Web of Science ®Google Scholar
• Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967–1976.
   PubMed Web of Science ®Google Scholar
• Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814–1820.
   PubMed Web of Science ®Google Scholar
• Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–523.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733.
   PubMed Web of Science ®Google Scholar
• Khan S, Siddique R, Bai Q, et al. Coronaviruses disease 2019 (COVID-19): causative agent, mental health concerns, and potential management options. J Infect Public Health. 2020b;13(12):1840–1844.
   PubMed Web of Science ®Google Scholar
• Bohn MK, Hall A, Sepiashvili L, et al. Pathophysiology of COVID-19: mechanisms underlying disease severity and progression. Physiology (Bethesda). 2020;35(5):288–301.
   PubMed Web of Science ®Google Scholar
• John Hopkins Coronavirus Resource Center. Johns Hopkins University & Medicine; [cited 2022 Aug 2]. Availabel from: https://coronavirus.jhu.edu/us-map.
   Google Scholar
• Sanche S, Lin YT, Xu C, et al. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis. 2020;26(7):1470–1477.
   PubMed Web of Science ®Google Scholar
• Diamond MS, Pierson TC. The challenges of vaccine development against a new virus during a pandemic. Cell Host Microbe. 2020;27(5):699–703.
   PubMed Web of Science ®Google Scholar
• Eichler HG, Cavaleri M, Enzmann H, et al. Clinical trials for COVID-19: can we better Use the short window of opportunity? Clin Pharmacol Ther. 2020;108(4):730–733.
   PubMed Web of Science ®Google Scholar
• Lee WS, Wheatley AK, Kent SJ, et al. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020;5(10):1185–1191.
   PubMed Web of Science ®Google Scholar
• Pottegard A, Kurz X, Moore N, et al. Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic. Pharmacoepidemiol Drug Saf. 2020;29(8):825–831.
   PubMed Web of Science ®Google Scholar
• Thanh Le T, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19(5):305–306.
   PubMed Web of Science ®Google Scholar
• Plavec Z, Pöhner I, Poso A, et al. Virus structure and structure-based antivirals. Curr Opin Virol. 2021;51:16–24.
   PubMed Web of Science ®Google Scholar
• Raj K, Kaur K, Gupta GD, et al. Current understanding on molecular drug targets and emerging treatment strategy for novel coronavirus-19. Naunyn Schmiedebergs Arch Pharmacol. 2021;394(7):1383–1402.
   PubMed Web of Science ®Google Scholar
• Patten JJ, Keiser PT, Gysi D, et al. Identification of druggable host targets needed for SARS-CoV-2 infection by combined pharmacological evaluation and cellular network directed prioritization both in vitro and in vivo. Available from: https://ssrn.com/abstract = 4038525.
   Google Scholar
• Heffron AS, McIlwain SJ, Amjadi MF, et al. The landscape of antibody binding in SARS-CoV-2 infection. PLoS Biol. 2021;19(6):e3001265.
   PubMed Web of Science ®Google Scholar
• Luan B, Huynh T, Cheng X, et al. Targeting proteases for treating COVID-19. J Proteome Res. 2020;19(11):4316–4326.
   PubMed Web of Science ®Google Scholar
• Shu T, Ning W, Wu D, et al. Plasma proteomics identify biomarkers and pathogenesis of COVID-19. Immunity. 2020;53(5):1108–1122. e5.
   PubMed Web of Science ®Google Scholar
• Finlay BB, McFadden G. Anti-Immunology: evasion of the host immune system by bacterial and viral pathogens. Cell. 2006;124(4):767–782.
   PubMed Web of Science ®Google Scholar
• Ernst JD. Antigenic variation and immune escape in the MTBC. Adv Exp Med Biol. 2017;1019:171–190.
   PubMed Web of Science ®Google Scholar
• Vossen MT, Westerhout EM, Soderberg-Naucler C, et al. Viral immune evasion: a masterpiece of evolution. Immunogenetics. 2002;54(8):527–542.
   PubMed Web of Science ®Google Scholar
• Raybould MIJ, Kovaltsuk A, Marks C, et al. CoV-AbDab: the coronavirus antibody database. Bioinformatics. 2021;37(5):734–735.
   PubMedGoogle Scholar
• Shang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581(7807):221–224.
   PubMed Web of Science ®Google Scholar
• Amrun SN, Lee CY, Lee B, et al. Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity. EBioMedicine. 2020;58:102911.
   PubMed Web of Science ®Google Scholar
• Kanduc D. From anti-SARS-CoV-2 immune responses to COVID-19 via molecular mimicry. Antibodies (Basel). 2020;9(3):33.
   PubMedGoogle Scholar
• Kong WH, Zhao R, Zhou JB, et al. Serologic response to SARS-CoV-2 in COVID-19 patients with different severity. Virol Sin. 2020;35(6):752–757.
   PubMed Web of Science ®Google Scholar
• Speiser DE, Bachmann MF. COVID-19: mechanisms of vaccination and immunity. Vaccines (Basel). 2020;8(3):404.
   PubMed Web of Science ®Google Scholar
• Zhang LX, Miao SY, Qin ZH, et al. Preliminary analysis of B- and T-cell responses to SARS-CoV-2. Mol Diagn Ther. 2020;24(5):601–609.
   PubMed Web of Science ®Google Scholar
• Arvin AM, Fink K, Schmid MA, et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature. 2020;584(7821):353–363.
   PubMed Web of Science ®Google Scholar
• Desheva YA, Mamontov AS, Nazarov PG. Contribution of antibody-dependent enhancement to the pathogenesis of coronavirus infections. AIMS Allergy and Immunology. 2020;4(3):50–59.
   Web of Science ®Google Scholar
• Wen J, Cheng Y, Ling R, et al. Antibody-dependent enhancement of coronavirus. Int J Infect Dis. 2020;100:483–489.
   PubMed Web of Science ®Google Scholar
• Roterman-Konieczna I. Identification of ligand binding site and protein-protein interaction area. Netherlands: Springer; 2013.
   Google Scholar
• Chain B, Greiff V, Textor J, et al. Editorial: methods and applications of computational immunology. Front Immunol. 2019;10:2818.
   PubMed Web of Science ®Google Scholar
• Clementi N, Mancini N, Castelli M, et al. Characterization of epitopes recognized by monoclonal antibodies: experimental approaches supported by freely accessible bioinformatic tools. Drug Discov Today. 2013;18(9-10):464–471.
   PubMed Web of Science ®Google Scholar
• Wang E, Sun H, Wang J, et al. End-Point binding free energy calculation with MM/PBSA and MM/GBSA: strategies and applications in drug design. Chem Rev. 2019a;119(16):9478–9508.
   PubMed Web of Science ®Google Scholar
• Weng G, Wang E, Chen F, et al. Assessing the performance of MM/PBSA and MM/GBSA methods. 9. prediction reliability of binding affinities and binding poses for protein-peptide complexes. Phys Chem Chem Phys. 2019;21(9):10135–10145.
   PubMedGoogle Scholar
• Rogers TF, Zhao F, Huang D, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science 2020;369(6506):956-963.
   PubMed Web of Science ®Google Scholar
• Wu Y, Wang F, Shen C, et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. 2020;368(6496):1274–1278.
   PubMed Web of Science ®Google Scholar
• Shi R, Shan C, Duan X, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020;584(7819):120–124.
   PubMed Web of Science ®Google Scholar
• Cao Y, Su B, Guo X, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell. 2020;182(1):73–84.
   PubMed Web of Science ®Google Scholar
• Ju B, Zhang Q, Ge J, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020;584(7819):115–119.
   PubMed Web of Science ®Google Scholar
• Hurlburt NK, Seydoux E, Wan YH, et al. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. Nat Commun. 2020;11(1):5413.
   PubMed Web of Science ®Google Scholar
• Case DA, Aktulga HM, Belfon K, et al. Amber. San Francisco: University of California; 2021.
   Google Scholar
• Tian C, Kasavajhala K, Belfon KAA, et al. ff19SB: amino-acid-specific protein backbone parameters trained against quantum mechanics energy surfaces in solution. J Chem Theory Comput. 2020;16(1):528–552.
   PubMed Web of Science ®Google Scholar
• Andújar SA, Gutiérrez LJ, Enriz RD, et al. Structure, interface stability and hot-spots identification for RBD(SARS-CoV-2):hACE2 complex formation. Molecular Simulation 2021;47(17):1443–1454.
   Google Scholar
• Gutierrez LJ, Andújar SA, Enriz RD, et al. Structural and functional insights into the anti-BACE1 Fab fragment that recognizes the BACE1 exosite. J Biomol Struct Dyn. 2014;32(9):1421–1433.
   PubMed Web of Science ®Google Scholar
• Siano A, Garibotto FF, Andújar SA, et al. Molecular design and synthesis of novel peptides from amphibians skin acting as inhibitors of cholinesterase enzymes. J Pept Sci. 2017;23(3):236–244.
   PubMed Web of Science ®Google Scholar
• Genheden S, Ryde U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov. 2015;10(5):449–461.
   PubMed Web of Science ®Google Scholar
• Sun H, Li Y, Tian S, et al. Assessing the performance of MM/PBSA and MM/GBSA methods. 4. accuracies of MM/PBSA and MM/GBSA methodologies evaluated by various simulation protocols using PDBbind data set. Phys Chem Chem Phys. 2014;16(31):16719–16729.
   PubMed Web of Science ®Google Scholar
• Rastelli G, Del Rio A, Degliesposti G, et al. Fast and accurate predictions of binding free energies using MM-PBSA and MM-GBSA. J Comput Chem. 2010;31(4):797–810.
   PubMed Web of Science ®Google Scholar
• Izadi S, Harris RC, Fenley MO, et al. Accuracy comparison of generalized born models in the calculation of electrostatic binding free energies. J Chem Theory Comput. 2018;14(3):1656–1670.
   PubMed Web of Science ®Google Scholar
• Wang E, Weng G, Sun H, et al. Assessing the performance of the MM/PBSA and MM/GBSA methods. 10. Impacts of enhanced sampling and variable dielectric model on protein-protein interactions. Phys Chem Chem Phys. 2019b;21(35):18958–18969.
   PubMed Web of Science ®Google Scholar
• Khan A, Tahir Khan M, Saleem S, et al. Structural insights into the mechanism of RNA recognition by the N-terminal RNA-binding domain of the SARS-CoV-2 nucleocapsid phosphoprotein. Comput Struct Biotechnol J. 2020a;18:2174–2184.
   PubMed Web of Science ®Google Scholar
• Xu D, Si Y, Meroueh SO. A computational investigation of small-molecule engagement of hot spots at protein-protein interaction interfaces. J Chem Inf Model. 2017;57(9):2250–2272.
   PubMed Web of Science ®Google Scholar
• Rocchia W. Poisson-boltzmann equation boundary conditions for biological applications. Math. and Comput. Model. 2005;41(10):1109–1118.
   Google Scholar
• Robinson MK, Monroe JI, Shell MS. Are AMBER force fields and implicit solvation models additive? A folding study with a balanced peptide test Set. J Chem Theory Comput. 2016;12(11):5631–5642.
   PubMed Web of Science ®Google Scholar
• Zeng J, Li Y, Zhang JZ, et al. Examination of the quality of various force fields and solvation models for the equilibrium simulations of GA88 and GB88. J Mol Model. 2016;22(8):177.
   PubMed Web of Science ®Google Scholar
• Bradshaw RT, Patel BH, Tate EW, et al. Comparing experimental and computational alanine scanning techniques for probing a prototypical protein-protein interaction. Protein Eng Des Sel. 2011;24(1-2):197–207.
   PubMed Web of Science ®Google Scholar
• Weiss GA, Watanabe CK, Zhong A, et al. Rapid mapping of protein functional epitopes by combinatorial alanine scanning. Proc Natl Acad Sci USA. 2000;97(16):8950–8954.
   PubMed Web of Science ®Google Scholar
• Aldeghi M, Bodkin MJ, Knapp S, et al. Statistical analysis on the performance of molecular mechanics Poisson-Boltzmann surface area versus absolute binding free energy calculations: bromodomains as a case study. J Chem Inf Model. 2017;57(9):2203–2221.
   PubMed Web of Science ®Google Scholar
• Martins SA, Perez MA, Moreira IS, et al. Computational alanine scanning mutagenesis: MM-PBSA vs TI. J Chem Theory Comput. 2013;9(3):1311–1319.
   PubMed Web of Science ®Google Scholar
• Massova I, Kollman PA. Computational alanine scanning To probe protein−protein interactions:  a novel approach to evaluate binding free energies. J. Am. Chem. Soc. 1999;121(36):8133–8143.
   Web of Science ®Google Scholar
• Moreira IS, Fernandes PA, Ramos MJ. Computational alanine scanning mutagenesis an improved methodological approach. J Comput Chem. 2007;28(3):644–654.
   PubMed Web of Science ®Google Scholar
• Novotny J, Bruccoleri RE, Davis M, et al. Empirical free energy calculations: a blind test and further improvements to the method. J Mol Biol. 1997;268(2):401–411.
   PubMed Web of Science ®Google Scholar
• Sharp KA. Electrostatic interactions in hirudin-thrombin binding. Biophys Chem. 1996;61(1):37–49.
   PubMed Web of Science ®Google Scholar
• Nguyen MN, Pradhan MR, Verma C, et al. The interfacial character of antibody paratopes: analysis of antibody-antigen structures. Bioinformatics. 2017;33(19):2971–2976.
   PubMed Web of Science ®Google Scholar
• Qiu T, Xiao H, Zhang Q, et al. Proteochemometric modeling of the antigen-antibody interaction: new fingerprints for antigen, antibody and epitope-paratope interaction. PLoS One. 2015;10(4):e0122416.
   PubMed Web of Science ®Google Scholar
• Van Oss CJ. Hydrophobic, hydrophilic and other interactions in epitope-paratope binding. Mol Immunol. 1995;32(3):199–211.
   PubMed Web of Science ®Google Scholar
• Ghorbani M, Brooks BR, Klauda JB. Critical sequence hotspots for binding of novel coronavirus to angiotensin converter enzyme as evaluated by molecular simulations. J Phys Chem B. 2020;124(45):10034–10047.
   PubMed Web of Science ®Google Scholar
• Tsai KC, Lee YC, Tseng TS. Comprehensive deep mutational scanning reveals the immune-escaping hotspots of SARS-CoV-2 receptor-binding domain targeting neutralizing antibodies. Front Microbiol. 2021;12:698365.
   PubMed Web of Science ®Google Scholar
• Della-Porta AJ, Westaway EG. A multi-hit model for the neutralization of animal viruses. J Gen Virol. 1978;38(1):1–19.
   PubMedGoogle Scholar
• Klasse PJ, Sattentau QJ. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J Gen Virol. 2002;83(Pt 9):2091–2108.
   PubMedGoogle Scholar
• Platt EJ, Gomes MM, Kabat D. Kinetic mechanism for HIV-1 neutralization by antibody 2G12 entails reversible glycan binding that slows cell entry. Proc Natl Acad Sci USA. 2012;109(20):7829–7834.
   PubMed Web of Science ®Google Scholar
• Reading SA, Dimmock NJ. Neutralization of animal virus infectivity by antibody. Arch Virol. 2007;152(6):1047–1059.
   PubMed Web of Science ®Google Scholar
• Chen J, Wang R, Wang M, et al. Mutations strengthened SARS-CoV-2 infectivity. J Mol Biol. 2020a;432(19):5212–5226.
   PubMed Web of Science ®Google Scholar
• Greaney AJ, Starr TN, Gilchuk P, et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host & Microbe. 2021;29(1):44–57.
   PubMed Web of Science ®Google Scholar
• Mercatelli D, Giorgi FM. Geographic and genomic distribution of SARS-CoV-2 mutations. Front Microbiol. 2020;11:1800.
   PubMed Web of Science ®Google Scholar
• Chen LL, Lu L, Choi CY, et al. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination. Clin Infect Dis. 2022a;74(9):1623–1630.
   PubMed Web of Science ®Google Scholar
• Chen X, Chen Z, Azman AS, et al. Neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination: a systematic review and pooled meta-analysis. Clin Infect Dis. 2022;74(4):734–742.
   PubMed Web of Science ®Google Scholar
• Ikegame S, Siddiquey MNA, Hung CT, et al. Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. Nat Commun. 2021;12(1):4598.
   PubMed Web of Science ®Google Scholar
• Starr TN, Czudnochowski N, Liu Z, et al. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature. 2021;597(7874):97–102.
   PubMed Web of Science ®Google Scholar
• Vasireddy D, Vanaparthy R, Mohan G, et al. Review of COVID-19 variants and COVID-19 vaccine efficacy: what the clinician should know? J Clin Med Res. 2021;13(6):317–325.
   PubMedGoogle Scholar
• Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021;27(4):622–625.
   PubMed Web of Science ®Google Scholar
• Wilson P, Changrob S, Fu Y, et al. Cross neutralization of emerging SARS-CoV-2 variants of concern by antibodies targeting distinct epitopes on spike. mBio. 2021;12(6):e0297521.
   PubMed Web of Science ®Google Scholar
• Yoo JH. What We Do know and Do Not Yet know about COVID-19 vaccines as of the beginning of the year 2021. J Korean Med Sci. 2021;36(6):e54.
   PubMed Web of Science ®Google Scholar
• Alenquer M, Ferreira F, Lousa D, et al. Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies. PLoS Pathog. 2021;17(8):e1009772.
   PubMed Web of Science ®Google Scholar
• Jeyanathan M, Afkhami S, Smaill F, et al. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020;20(10):615–632.
   PubMed Web of Science ®Google Scholar
• Koopman JS, Simon CP, Getz WM, et al. Modeling the population effects of escape mutations in SARS-CoV-2 to guide vaccination strategies. Epidemics. 2021;36:100484.
   PubMed Web of Science ®Google Scholar
• Tregoning JS, Flight KE, Higham SL, et al. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21(10):626–636.
   PubMed Web of Science ®Google Scholar
• Van Egeren D, Novokhodko A, Stoddard M, et al. Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein. PLoS One. 2021;16(4):e0250780.
   PubMed Web of Science ®Google Scholar
• Bian C, Zhang X, Cai X, et al. Conserved amino acids W423 and N424 in receptor-binding domain of SARS-CoV are potential targets for therapeutic monoclonal antibody. Virology. 2009;383(1):39–46.
   PubMed Web of Science ®Google Scholar
• Chen W-H, Hotez PJ, Bottazzi ME. Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19. Human Vaccines & Immunotherapeutics. 2020b;16(6):1239–1242.
   PubMed Web of Science ®Google Scholar
• Zhou D, Duyvesteyn HME, Chen CP, et al. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nat Struct Mol Biol. 2020;27(10):950–958.
   PubMed Web of Science ®Google Scholar
• Jian JW, Chen HS, Chiu YK, et al. Effective binding to protein antigens by antibodies from antibody libraries designed with enhanced protein recognition propensities. MAbs. 2019;11(2):373–387.
   PubMed Web of Science ®Google Scholar
• Schreiber G. Protein–protein interaction interfaces and their functional implications. In: Roy S., Fu H. editors. Protein–protein interaction regulators. London : The Royal Society of Chemistry; 2020. p. 1–24.
   Google Scholar
• Sela-Culang I, Kunik V, Ofran Y. The structural basis of antibody-antigen recognition. Front Immunol. 2013;4:302.
   PubMed Web of Science ®Google Scholar
• Yu CM, Peng HP, Chen IC, et al. Rationalization and design of the complementarity determining region sequences in an antibody-antigen recognition interface. PLoS One. 2012;7(3):e33340.
   PubMed Web of Science ®Google Scholar
• Kunik V, Ashkenazi S, Ofran Y. Paratome: an online tool for systematic identification of antigen-binding regions in antibodies based on sequence or structure. Nucleic Acids Res. 2012a;40(Web Server issue):W521–W524.
   PubMedGoogle Scholar
• Kunik V, Peters B, Ofran Y. Structural consensus among antibodies defines the antigen binding site. PLoS Comput Biol. 2012b;8(2):e1002388.
   PubMed Web of Science ®Google Scholar
• Clark LA, Ganesan S, Papp S, et al. Trends in antibody sequence changes during the somatic hypermutation process. J Immunol. 2006;177(1):333–340.
   PubMed Web of Science ®Google Scholar
• Muecksch F, Weisblum Y, Barnes CO, et al. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity. 2021;54(8):1853–1868.
   PubMed Web of Science ®Google Scholar
• Birtalan S, Zhang Y, Fellouse FA, et al. The intrinsic contributions of tyrosine, serine, glycine and arginine to the affinity and specificity of antibodies. J Mol Biol. 2008;377(5):1518–1528.
   PubMed Web of Science ®Google Scholar
• Wan Y, Shang J, Graham R, et al. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94(7):e00127–20.
   PubMed Web of Science ®Google Scholar